ADI-001 led to reductions in disease activity for seven lupus patients in a clinical trial, with no serious side effects reported, data show.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback